TY - JOUR
T1 - Severe Paediatric Asthma Collaborative in Europe
T2 - real-world data on children on biologics
AU - Liu, Norrice M.
AU - Pijnenburg, Mariëlle W.
AU - Deschildre, Antoine
AU - de Mir-Messa, Ines
AU - Adalen, Sigve
AU - Amat, Flore
AU - Antonino, Luna
AU - Biermé, Priscille
AU - Bravo-Lopez, Maynor
AU - Carlsen, Karin C.L.
AU - Carraro, Silvia
AU - Cros, Pierrick
AU - Delestrain, Celine
AU - Garcia, Carolina Diaz
AU - Epaud, Ralph
AU - Fenu, Grazia
AU - Ferraro, Valentina A.
AU - Fleming, Louise
AU - Hanssens, Laurence
AU - Heine, Anouk
AU - Labouret, Géraldine
AU - Leoni, Maria Chiara
AU - Licari, Amelia
AU - Lombardi, Enrico
AU - Neyra, Alejandro Lopez
AU - Marguet, Christophe
AU - Mazenq, Julie
AU - Tarazona, Santiago Pérez
AU - Díaz, Juan Carlos Ramos
AU - Schweitzer, Cyril
AU - Spada, Elena
AU - Molina, José Valverde
AU - Verhulst, Stijn
AU - Wanin, Stéphanie
AU - Rusconi, Franca
N1 - Copyright ©The authors 2025 This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.
PY - 2025/6/23
Y1 - 2025/6/23
N2 - Introduction:Real-world data on children with severe asthma is scarce. We report characteristics of children with severe asthma already on biologics, enrolled in the Severe Paediatric Asthma Collaborative in Europe, a clinical research collaboration of the European Respiratory Society. Methods:We describe patient’s characteristics including asthma control assessed with Global Initiative for Asthma (GINA) criteria, composite asthma severity index (CASI), exacerbations, unscheduled medical attendances, lung function and quality of life in children on biologic treatment because of severe asthma. We also assessed previous biologics use. Forced expiratory volume in 1 s, CASI, GINA, Paediatric Asthma Quality of Life Questionnaire score, exacerbations, unscheduled medical attendance and hospital admission comparisons in patients treated with different biologics were adjusted by age, sex and biologic therapy duration. Results: Among the 250 children (median age 13.2 years) recruited, 56.8% used omalizumab, 21.6% mepolizumab and 21.6% dupilumab. At enrolment, the dupilumab group was older (median 15.0 years), while the omalizumab group had been on biologic treatment the longest (median 622 days). Overall, 27% and 8% had partly controlled and uncontrolled asthma respectively, according to GINA. In the last 12 months, 52% and 29% had at least one and two exacerbations, respectively; airflow obstruction was found in 33%. 10% were admitted to hospital due to exacerbation. A previous switch from another biologic was recorded in 16%, predominantly due to nonresponse. Conclusions: Most children on biologics obtained good symptom control, but many still experienced asthma attacks. Switching between biologics was substantial. There is still an unmet need in severe paediatric asthma.
AB - Introduction:Real-world data on children with severe asthma is scarce. We report characteristics of children with severe asthma already on biologics, enrolled in the Severe Paediatric Asthma Collaborative in Europe, a clinical research collaboration of the European Respiratory Society. Methods:We describe patient’s characteristics including asthma control assessed with Global Initiative for Asthma (GINA) criteria, composite asthma severity index (CASI), exacerbations, unscheduled medical attendances, lung function and quality of life in children on biologic treatment because of severe asthma. We also assessed previous biologics use. Forced expiratory volume in 1 s, CASI, GINA, Paediatric Asthma Quality of Life Questionnaire score, exacerbations, unscheduled medical attendance and hospital admission comparisons in patients treated with different biologics were adjusted by age, sex and biologic therapy duration. Results: Among the 250 children (median age 13.2 years) recruited, 56.8% used omalizumab, 21.6% mepolizumab and 21.6% dupilumab. At enrolment, the dupilumab group was older (median 15.0 years), while the omalizumab group had been on biologic treatment the longest (median 622 days). Overall, 27% and 8% had partly controlled and uncontrolled asthma respectively, according to GINA. In the last 12 months, 52% and 29% had at least one and two exacerbations, respectively; airflow obstruction was found in 33%. 10% were admitted to hospital due to exacerbation. A previous switch from another biologic was recorded in 16%, predominantly due to nonresponse. Conclusions: Most children on biologics obtained good symptom control, but many still experienced asthma attacks. Switching between biologics was substantial. There is still an unmet need in severe paediatric asthma.
UR - https://www.scopus.com/pages/publications/105009130861
U2 - 10.1183/23120541.00709-2024
DO - 10.1183/23120541.00709-2024
M3 - Article
C2 - 40551791
AN - SCOPUS:105009130861
SN - 2312-0541
VL - 11
JO - ERJ Open Research
JF - ERJ Open Research
IS - 3
M1 - 00709-2024
ER -